

# Association of PTPN22 (rs2476601) and STAT4 (rs7574865) polymorphisms with Rheumatoid Arthritis in the Western Algerian population

Fodil M<sup>1</sup>, Benzaoui A<sup>2</sup>, Zemani-Fodil F<sup>1</sup>, Aberkane M<sup>1</sup>, Boughrara W<sup>1</sup>, Saidi-Mehtar N<sup>1</sup>, Petit-Teixeira E<sup>3</sup>, Boudjema A<sup>1</sup>

ACTA REUMATOL PORT. ONLINE FIRST

## ABSTRACT

**Aim:** The aim of the present study was to replicate the association of five risk gene polymorphisms (PTPN22-rs2476601, STAT4-rs7574865, 6q23-rs6927172, IRF5-rs2004640 and TRAF1/C5-rs10818488) with RA in a specific population of the Western Algeria.

**Material and methods:** The study group comprised 110 patients with RA and 197 ethnically matched healthy control subjects. All polymorphisms were genotyped using predesigned TaqMan® assays. Allele and genotype frequencies in patients and control subjects were compared by chi-square test and odds ratios with 95% confidence intervals. Correction for multiple testing was carried out using the Bonferroni adjustment.

**Results:** Statistically significant associations with RA were detected. The strongest signal was obtained for PTPN22-rs2476601 with an allelic Pvalue  $3.32 \times 10^{-11}$  (OR = 9.83, 95% CI [4.28 – 22.56]). A second significant association was obtained with STAT4-rs7574865 (allelic Pvalue =  $4 \times 10^{-3}$ ; OR = 1.75, 95% CI [1.16–2.63]). The third SNP, 6q23-rs6927172, showed a significant result of association with RA, but missed our criteria for significance at allelic level after Bonferroni's correction (allelic Pvalue = 0.027; OR = 0.64, 95% CI [0.42 – 0.97]). Finally, IRF5-rs2004640 and TRAF1/C5-rs10818488 showed a significant association only at genotypic level (Pvalues:  $3 \times 10^{-4}$  and  $2.9 \times 10^{-3}$  respectively) but did not reach statistical significance when comparing allele frequencies (Pvalues: 0.96 and 0.21 respectively).

**Conclusions:** From this initial study, we can conclude that PTPN22-rs2476601 and STAT4-rs7574865 poly-

morphisms are clearly associated with the risk of RA in the Western Algerian population.

**Keywords:** Rheumatoid arthritis; Algerians; PTPN22.

## INTRODUCTION

Rheumatoid arthritis (RA) is a complex autoimmune disease characterized by altered inflammatory and impaired immune responses causing immune-mediated destruction of tissues and organs. Although the aetiology of this autoimmune disease is not completely known, it is nowadays clearly demonstrated that both genetic and environmental factors contribute to the development of RA.

Previous genetic and family studies indicated a significant genetic contribution to RA development<sup>1</sup>. Genetic association of *HLA-DRB1* and RA has been well established in multiple ethnic groups. However, the *HLA* region contributes only 30–50% of genetic component for RA<sup>2</sup>.

Advances in genotyping technology have facilitated the application of whole genome association approaches to identify disease causal variants. Recent and several genome-wide and candidate-gene studies reported additional evidence for association of single nucleotide polymorphisms (SNPs) markers in several candidate genes and/or loci such *PTPN22*, *STAT4*, *OLIG3/TNFAIP3* (6q23), *IRF5* and *TRAF1/C5* loci with RA<sup>3,4</sup>. All these genes are involved in the immune response and/or its regulation.

A non-synonymous single nucleotide polymorphism (SNP) in the gene encoding *protein tyrosine phosphatase non-receptor 22* (*PTPN22*) is considered as the second risk factor of susceptibility to RA after *HLA*<sup>5</sup>. The *STAT4* locus has been identified as a confirmed RA susceptibility locus in UK, Korean, Swedish, US, Greek, Co-

1. Laboratoire de Génétique Moléculaire et Cellulaire/Université des Sciences et de la Technologie d'Oran Mohamed Boudiaf (USTO-MB), Algeria

2. Service de Rhumatologie / CHUO (Oran), Algeria

3. GenHotel-EA3886/Evry-Val d'Essonne University, Evry-Genopole, France.

lombian, Spanish and US populations<sup>6–11</sup>. A locus, mapped between *OLIG3* and *TNFAIP3* on chromosome 6q was identified in a genome-wide association study (GWAS) of seven common diseases, including RA, carried out by the WTCCC (The Wellcome Trust Case Control Consortium)<sup>4</sup>. Association with this locus 6q23 has been replicated in populations from the UK and USA<sup>12,13</sup>. The recent finding of an association between the *IRF5* gene and systemic lupus erythematosus (SLE)<sup>14</sup>, which has been replicated in multiple populations, as well as the association between *IRF5* and RA<sup>15</sup> and inflammatory bowel diseases (IBD)<sup>16</sup>, provides additional support for the important role of *IRF5* and the type I Interferon (*IFN*) system in autoimmune diseases. Finally, a GWAS in American and Swedish populations identified a novel locus mapping between *TRAF1* and *C5* loci associated with RA<sup>17</sup>. This association has been replicated in samples from Greece, Netherlands and North American populations<sup>17,18</sup>.

This study was initiated to replicate, in a specific population of the Western Algeria, the association between these five defined genetic markers and RA. To our knowledge, this is the first study to be realized in the Western Algerian population in order to find a genetic association between these polymorphisms and RA.

## PATIENTS AND METHODS

**Subjects:** The study group comprised 110 RA patients from unrelated families living in Oran region (Western Algeria). A control group comprising 197 ethnically matched healthy volunteers have been included in the study (Table 1).

All RA patients met the American Rheumatism Association 1987 revised criteria 19 and were recruited

from department of Rheumatology of Oran hospital “CHUO” (*Centre Hospitalo-Universitaire d’Oran*). Ethnic bias within the population studied was minimized by excluding patients that were not of western Algerian origin. Western Algerian origin was defined as having the four grandparents of each individual possessing a western Algerian ancestry. The control group was recruited on the same basis of ethnic and geographic characteristics. Healthy volunteers were recruited through a local media campaign followed by selection of individuals who fulfilled our criteria: having a Western Algerian origin, absence of consanguinity in parents and absence of any autoimmune disease for the volunteers or their parents.

Informed consent was obtained from all subjects and the study was conducted according to the declaration of Helsinki Principles, and the ethics committee of *Centre Hospitalo-Universitaire d’Oran (CHUO, Oran, Algeria)* approved the study.

**DNA extraction:** Peripheral Blood was collected into 5 ml tubes containing EDTA and stored at  $-20^{\circ}\text{C}$  until analysis. Genomic DNA was purified from fresh peripheral blood leukocytes by standard DNA extraction methods<sup>20</sup>.

**Molecular genotyping:** Genes and SNPs choice was based on previous published data on RA association from genome-wide and candidate-gene studies<sup>3,4</sup> (Table II). *6q23-rs6927172* was chosen because it was in Linkage Disequilibrium (LD) in the Caucasian population with *6q23-rs6920220*, another SNP in the same genomic region which was confirmed as a risk factor for RA<sup>4,13</sup>.

Genotyping of the five gene polymorphisms was carried out with a Taqman® 5’ allelic discrimination assay (Table II). It was performed on an ABI-7500 real-time polymerase chain reaction (PCR) machine (Applied Biosystems, now Life Technologies, Foster City,

**TABLE I. POPULATION CHARACTERISTICS**

Characteristics	RA Cases (%)	Healthy Controls (%)	P value
Number of Subjects	110	197	–
Men	11 (10%)	89 (45.18%)	NS
Women	99 (90%)	108 (54.82%)	NS
Age (years)	48 + 30.5	40 + 22	NS
Rheumatoid Factor +	31 (32%)	ND	–
Rheumatoid Factor –	66 (68%)	ND	–

Values are presented as the mean  $\pm$  SD or number.

RA: Rheumatoid Arthritis; ND: Not Done; NS: Not significant

TABLE II. SNP MARKERS USED IN ANALYSIS

Gene/Locus	db SNP ID	Assay ID	SNP (NCBI Build)	Location	Gene/Function
PTPN22	rs2476601	C__16021387_20	A/G	Chr.1: 114377568	Missense mutation
STAT4	rs7574865	C__29882391_10	G/T	Chr.2:191964633	Intron
6q23 (TNFAIP3/OLIG3)	rs6927172	C__1575580_10	C/G	Chr.6: 138002175	Intergenic
IRF5	rs2004640	C__9491614_10	G/T	Chr.7: 128578301	Intron
TRAF1/C5	rs10818488	C__2783655_10	A/G	Chr.9: 123705087	Intergenic

db: data base ; SNP: single nucleotide polymorphism ; Chr: chromosome ; NCBI: National Center for Biotechnology Information

CA, USA) according to the manufacturer's protocol. Genotyping of each sample was automatically attributed using ABI PRISM® 7500 Sequence Detection System software "SDS" for allelic discrimination.

**Quality control:** For quality control, positive and negative controls (from CEPH "Centre d'Étude du polymorphisme Humain") were co-genotyped in each genotyping assay and additional 10% of randomly selected duplicates were included. No discrepancy between duplicates was observed in the genotyping data of the five selected SNPs. All control tests had greater than 99% genotype passing rates.

**Statistical analyses:** Prior to association tests, we checked the Hardy–Weinberg equilibrium in the control group using a standard chi-square test. Results from the control subjects and RA unrelated patients were compared using the chi-square test (2x2 contingency tables) for statistical significance.

The genotype relative risk (GRR) method (a single genotype vs. the others) was used to compare the genotype distribution in controls and patients. The GRR test adjusts the genotype frequencies in the controls to the expected Hardy–Weinberg proportions and yields more accurate risk estimates<sup>21</sup>.

P values < 0.05 were considered statistically significant. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated with Woolf's method. Odds ratio was calculated considering the risk allele of each SNP or considering genotypes containing the risk alleles. Correction for multiple testing was carried out using the Bonferroni adjustment. The significance of the p value was assessed at 0.01 (0.05/5 considering 5 SNPs tested).

## RESULTS

Demographic and clinical characteristics of all subjects

are summarized in Table I. The observed sex ratio of 9 females for 1 male seems to be an ethnic characteristic of the Algerian population as it has been reported in RA cohorts from other Algerian regions (data not published). There is a difference of sex ratio between RA and controls groups but it is not statistically significant.

We analysed five gene polymorphisms (*PTPN22*-rs2476601, *STAT4*-rs7574865, *TNFAIP3*-rs6927172, *IRF5*-rs2004640 and *TRAF1/C5*-rs10818488) with a prior evidence of association with RA in numerous genome-wide association studies and candidate-gene approaches<sup>3,4</sup>. For all five SNP polymorphisms no deviation from the Hardy–Weinberg equilibrium was observed in the control group (data not shown). We observed a clear significant association between two SNPs (*PTPN22*-rs2476601 and *STAT4*-rs7574865) and RA in our population, since the other three SNPs (*6q23*-rs6927172, *IRF5*-rs2004640 and *TRAF1/C5*-rs10818488) did not reach statistical significance at allelic level (Table III).

The strongest result was obtained with *PTPN22*-rs2476601 with an allelic Pvalue =  $3.32 \times 10^{-11}$  (OR = 9.83, 95% CI [4.28 – 22.56]) (table III). Moreover, the presence of at least one copy of T-rs2476601 allele was significantly different between RA patients and healthy controls (Pvalue=  $8.36 \times 10^{-9}$ ; OR= 12.08 and 95% CI [4.86 - 33.42]).

Another significant association was obtained with *STAT4*-rs7574865 (allelic Pvalue =  $4 \times 10^{-3}$ ; OR = 1.75, 95% CI [1.16 – 2.63]). The presence of at least one copy of T-rs7574865 allele showed a significant difference between RA patients and healthy subjects (Pvalue =  $8 \times 10^{-4}$ ; OR = 2.23 and 95% CI [1.35 – 3.71]).

The third SNP, *6q23*-rs6927172, showed a significant association (allelic-Pvalue = 0.027 ; OR = 0.64, 95% CI [0.42 – 0.97]), but missed our criteria for sig-

TABLE III. SNP ASSOCIATION ANALYSIS IN RA-HS CASE-CONTROL SAMPLE

Gene / SNP	Genotype/ /Allele	RA Patients n=110 (%)	Controls n=197 (%)	X <sup>2</sup>	P value	OR (95% CI)
PTPN22 rs2476601	TT	1 (1)	0 (0)	45.5	$1.31 \times 10^{-10}$	9.83 (4.28 – 22.56)
	TC	33 (30)	7 (4)			
	CC	76 (69)	189 (96)			
	T	35 (16)	7 (2)	43.97	$3.32 \times 10^{-11}$	12.08 (4.86 – 33.42)
	C	185 (84)	385 (98)			
STAT4 rs7574865	TT + TC	34 (31)	7 (4)	45.38	$8.36 \times 10^{-9}$	12.08 (4.86 – 33.42)
	CC	76 (69)	189 (96)			
	GG	53 (48)	133 (68)	11.65	$2.9 \times 10^{-3}$	1.75 (1.16 – 2.63)
	GT	53 (48)	57 (29)			
	TT	4 (4)	7 (4)			
6q23 rs6927172	T	61 (28)	71 (18)	7.88	$4 \times 10^{-3}$	2.23 (1.35 – 3.71)
	G	159 (72)	323 (82)			
	GT + TT	57 (52)	64 (32)	11.05	$8 \times 10^{-4}$	2.05 (1.26 – 3.32)
	GG	53 (48)	133 (68)			
	CC	58 (53)	135 (70)	11.39	$3 \times 10^{-3}$	0.64 (0.42 – 0.97)
IRF5 rs2004640	CG	49 (45)	50 (26)			
	GG	3 (2)	9 (4)			
	G	55 (25)	68 (18)	4.86	0.027*	2.72 (1.2 – 6.32)
	C	165 (75)	320 (82)			
	CG + GG	52 (47)	59 (30)	8.61	$3 \times 10^{-3}$	1.01 (0.72 – 1.4)
TRAF1/C5 rs10818488	CC	58 (53)	135 (70)			
	GG	9 (8)	38 (19)	15.84	$3 \times 10^{-4}$	0.81 (0.57 – 1.13)
	GT	80 (73)	97 (50)			
	TT	21 (19)	60 (31)			
	T	122 (55)	217 (56)	0.002	0.96	1.13 (0.68 – 1.87)
TRAF1/C5 rs10818488	G	98 (45)	173 (44)			
	GT + TT	101 (92)	157 (81)	6.9	$8.6 \times 10^{-3}$	1.13 (0.68 – 1.87)
	GG	9 (8)	38 (19)			
	AA	7 (6)	38 (19)	11.63	$2.9 \times 10^{-3}$	1.13 (0.68 – 1.87)
	AG	69 (63)	92 (47)			
	GG	34 (31)	66 (34)			
TRAF1/C5 rs10818488	A	83 (38)	168 (43)	1.53	0.21	1.13 (0.68 – 1.87)
	G	137 (62)	224 (57)			
	AA + AG	76 (69)	130 (66)	0.24	0.62	1.13 (0.68 – 1.87)
	GG	34 (31)	66 (34)			
	GG	34 (31)	66 (34)			

\*P value not significant after Bonferroni's correction (alpha=0.01)

RA: rheumatoid arthritis; OR: Odds Ratio; SNP: single nucleotide polymorphism

nificance after Bonferroni's correction. However, at the genotypic level, the Pvalue for 6q23-rs6927172 was still significant after Bonferroni's correction (genotypic-Pvalue =  $3 \times 10^{-3}$ ) (Table III).

Finally, IRF5-rs2004640 and TRAF1/C5-rs10818488 showed a significant association only at genotypic level (P values:  $3 \times 10^{-4}$  and  $2.9 \times 10^{-3}$  respectively) but

did not reach significance when comparing allele frequencies (P values: 0.96 and 0.21 respectively).

## DISCUSSION

The aim of the present study was to replicate, among

the specific Western Algerian population, the association of these five risk gene polymorphisms with RA.

A clear significant association was obtained between RA and two SNPs (*PTPN22*-rs2476601 and *STAT4*-rs7574865) in our population, since the other three SNPs (*6q23*-rs6927172, *IRF5*-rs2004640 and *TRAF1/C5*-rs10818488) did not reach statistical significance (Table III). This preliminary study in the Western Algerian population is in accordance with previous studies reporting the same findings in several populations.

The strongest association with RA was observed with *PTPN22*-rs2476601 polymorphism. The first study of the association of *PTPN22*-rs2476601 with RA was conducted in 2004<sup>5</sup>. Since, numerous studies confirmed this association in different populations including French<sup>22</sup>, UK<sup>23</sup>, Finnish<sup>24</sup>, Swedish<sup>25</sup>, German<sup>26</sup>, Dutch<sup>27</sup>, Spanish<sup>28</sup> and Canadian<sup>29</sup> populations. However, a study in a Japanese population could not confirm for association as the causal variant was found to have a very low minor allele frequency<sup>30</sup>.

Two other studies in Tunisians, a population with a close ethnic origin to Algerians, reported controversial results about the association of *PTPN22*-rs2476601 polymorphism with RA. Indeed, Chabchoub *et al.*<sup>31</sup> reported a lack of association while Sfar *et al.*<sup>32</sup> confirmed the association with RA, through two independent case-control studies from distinct regions in Tunisia.

The second most important association was detected with *STAT4*-rs7574865 (allelic Pvalue =  $4 \times 10^{-3}$ ; OR = 1.75, 95% CI [1.16 – 2.63]). Moreover, the presence of at least one copy of T-rs7574865 allele showed a significant difference between RA patients and healthy subjects (Pvalue =  $8 \times 10^{-4}$ ; OR = 2.23 and 95% CI [1.35 – 3.71]). Our results are in accordance with all previous studies on association of *STAT4*-rs7574865 with RA in different populations<sup>6–11</sup>.

*6q23*-rs6927172 showed a trend of association with RA in our study. However, it did not reach statistical significance after multiple test correction when comparing allelic frequencies. This could be caused by our study design (case-control and the relatively reduced sample size) or represent a true ethnic characteristic of the Western Algerian population. This observation is not very different from a study from another Mediterranean population (Spanish) which reported a weak association between SNPs located in this genomic region and RA<sup>33</sup>. Indeed, Dieguez-Gonzalez *et al.* reported a weak evidence of association both in the *6q23* intergenic region and in the *TNFAIP3* locus. Overall, statistical association was best explained by the interde-

pendent contribution of SNPs from the two loci *TNFAIP3* and the *6q23* intergenic region. Another study in Tunisians reported a trend of association between rs6920220 and RA<sup>34</sup>. It is now clear that *6q23* locus is a demonstrated candidate for a role in RA. However, our study only provides a suggestive evidence of the involvement of this locus in RA susceptibility.

Concerning *IRF5*-rs2004640 a significant association was obtained only at genotypic level (Pvalues =  $3 \times 10^{-4}$ ) but did not reach statistical significance when comparing allele frequencies (Pvalue = 0.96). A similar result was obtained in the Tunisian population by Maaiej *et al.*<sup>35</sup>; in this study, no significant difference was found at the allelic level between RA patients and Healthy controls. However, the genotype TT was more frequent in patients with RA (42.1%) than in the healthy controls (31.4%) (P value = 0.01). Another study reported no RA linkage in 100 French Caucasian trio families; there was no over-transmission of the *IRF5*-rs2004640-T allele from heterozygotic parents to affected patients (P value=0.76)<sup>36</sup>. This could be explained by the fact that the association effect is brought by the homozygote genotype TT independently from the allele frequency.

Similarly to *IRF5*-rs2004640, *TRAF1/C5*-rs10818488 showed a significant association at genotypic level (P values =  $2.9 \times 10^{-3}$ ) but did not reach statistical significance when comparing allele frequencies (Pvalue = 0.21). Again, this could be explained, by the study design or represent a true ethnic characteristic of the Western Algerian population. Zervou *et al.* and Kurreeman *et al.*<sup>6,18</sup> reported an association between this region and RA in large-scale genetic association studies, while a genome-wide study performed by the Wellcome Trust failed to identify this region as a candidate for RA<sup>4</sup>.

Finally, the case-control approach cannot avoid imperfect matching between cases and controls, and the association may be consequently under- or overestimated. The family-based studies are known to be more robust, avoiding this imperfect matching and testing directly Mendel's law by the transmission disequilibrium test.

The current report is the first clear demonstration of non-MHC related susceptibility gene for RA that confers a risk among the Western Algerian population. It is worthwhile to conduct additional population-based studies, including larger groups to confirm these findings and to analyze other genetic factors in the Algerian population.

## CORRESPONDENCE TO

Mostefa Fodil  
Laboratoire de Génétique Moléculaire et Cellulaire,  
Université des Sciences et de la Technologie d'Oran Mohamed  
Boudiaf (USTO-MB), BP 1505, Oran El M'Naouer, Algeria  
E-mail: mostefa.fodil@gmail.com

## REFERENCES

- Wandstrat A and Wakeland E. The genetics of complex autoimmune diseases: non-MHC susceptibility genes. *Nat Immunol* 2001; 2:802–809. doi:10.1038/ni0901-802.
- Bowes J and Barton A. Recent advances in the genetics of RA susceptibility. *Rheumatology* (Oxford) 2008; 47:399–402.
- Stahl EA, Raychaudhuri S, Remmers EF, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. *Nat Genet* 2010; 42:508–514.
- The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 2007; 447:661–678.
- Begovich AB, Carlton VEH, Honigberg LA, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. *Am J Hum Genet* 2004; 75:330–337.
- Zervou MI, Sidiropoulos P, Petraki E, et al. Association of a TRAF1 and a STAT4 gene polymorphism with increased risk for rheumatoid arthritis in a genetically homogeneous population. *Hum Immunol* 2008; 69: 567–571.
- Barton A, Thomson W, Ke X, et al. Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. *Hum Mol Genet* 2008; 17: 2274–2279.
- Lee HS, Remmers EF, Le JM, Kastner DL, Bae S-C, Gregersen PK. Association of STAT4 with rheumatoid arthritis in a Korean population. *Mol Med* 2007; 13: 455–460.
- Palomino-Morales RJ, Rojas-Villarraga A, Gonzalez CI, Ramirez G, Anaya JM, Martin J. STAT4 but not TRAF1/C5 variants influence the risk of developing rheumatoid arthritis and systemic lupus erythematosus in Colombians. *Genes Immun* 2008; 9:379–382.
- Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. *N Engl J Med* 2007; 357:977–986.
- Orozco G, Alizadeh BZ, Delgado-Vega AM, et al. Association of STAT4 with rheumatoid arthritis: a replication study in three European populations. *Arthritis Rheum* 2008; 58:1974–1980.
- Plenge RM, Cotsapas C, Davies L, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. *Nat Genet* 2007; 39:1477–1482.
- Thomson W, Barton A, Ke X, et al. Rheumatoid arthritis association at 6q23. *Nat Genet* 2007; 39:1431–1433.
- Sigurdsson S, Nordmark G, Goring HH, et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. *Am J Hum Genet* 2005; 75:528–537.
- Sigurdsson S, Padyukov L, Kurreeman FA, et al. Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. *Arthritis Rheum* 2007; 56: 2202–2210.
- Dideberg V, Kristjansdottir G, Milani L, et al. An insertion-deletion polymorphism in the interferon regulatory factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. *Hum Mol Genet* 2007; 16: 3008–3016.
- Plenge RM, Seielstad M, Padyukov L, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis – a genome wide study. *N Engl J Med* 2007; 357:1199–1209.
- Kurreeman FA, Padyukov L, Marques RB, et al. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis. *PLoS Med* 2007; 4:e278.
- Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988; 31:315.
- Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res.* 1988; 16:1215.
- Lathrop GM. Estimating genotype relative risks. *Tissue Antigens* 1983; 22: 160–166.
- Michou L, Lasbleiz S, Rat AC, et al. Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene. *Proc Natl Acad Sci USA* 2007; 104:1649–1654.
- Hinks A, Barton A, John S, et al. Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. *Arthritis Rheum* 2005; 52:1694–1699.
- Seldin MF, Shigeta R, Laiho K, et al. Finnish case-control and family studies support PTPN22 R620W polymorphism as a risk factor in rheumatoid arthritis, but suggest only minimal or no effect in juvenile idiopathic arthritis. *Genes Immun* 2005; 6: 720–722.
- Plenge RM, Padyukov L, Remmers EF, et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. *Am J Hum Genet* 2005; 77:1044–1060.
- Pierer M, Kaltenhauser S, Arnold S, et al. Association of PTPN22 1858 single nucleotide polymorphism with rheumatoid arthritis in a German cohort: higher frequency of the risk allele in male compared to female patients. *Arthritis Res Ther* 2006; 8:R75.
- Zhernakova A, Eerligh P, Wijmenga C, Barrera P, Roep BO, Koelman BP. Differential association of the PTPN22 coding variant with autoimmune diseases in a Dutch population. *Genes Immun* 2005; 6:459–461.
- Orozco G, Sanchez E, Gonzalez-Gay MA, et al. Association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. *Arthritis Rheum* 2005; 52:219–224.
- van Oene M, Wintle RF, Liu X, et al. Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations. *Arthritis Rheum* 2005; 52: 1993–1998.
- Ikari K, Momohara S, Inoue E, et al. Haplotype analysis revealed no association between the PTPN22 gene and RA in a Japanese population. *Rheumatology* 2006; 45:1345–1348.
- Chabchoub G, Teixeira EP, Maalej A, et al. The R620W polymorphism of the protein tyrosine phosphatase 22 gene in autoimmune thyroid diseases and rheumatoid arthritis in the Tunisian population. *Ann Hum Biol* 2009; 36:342–349.
- Sfar I, Dhaouadi T, Habibi I, et al. Functional polymorphisms of PTPN22 and FCGR genes in Tunisian patients with rheu-

- matoid arthritis. Arch Inst Pasteur Tunis 2009; 86:51-62.
33. Dieguez-Gonzalez R, Calaza M, Perez-Pampin E, et al. Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-kappaB and the neighbour intergenic 6q23 region in rheumatoid arthritis susceptibility. Arthritis Res Ther 2009; 2:R42. doi: 10.1186/ar2650.
34. Ben Hamad M, Cornelis F, Maalej A, Petit-Teixeira E. A Tunisian case-control association study of a 6q polymorphism in rheumatoid arthritis. Rheumatol Int. 2012; 32:1849-1850. doi: 10.1007/s00296-011-1996-6.
35. Maalej A, Hamad MB, Rebaï A, et al. Association of IRF5 gene polymorphisms with rheumatoid arthritis in a Tunisian population. Scand J Rheumatol. 2008; 37:414-418.
36. Garnier S, Dieudé P, Michou L, et al. IRF5 rs2004640-T allele, the new genetic factor for systemic lupus erythematosus, is not associated with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 828-831.